ECR 2024 – European Congress of Radiology
Creating a world where cancer can’t hide.
Discover the ProFound Breast AI Health Suite at ECR 2024
iCAD Booth X1 AI-35 | Vienna, Austria | February 28 – March 3, 2024
Cancer wins when it hides
When it comes to cancer, hide and seek is no game.
iCAD is creating a world where cancer can’t hide with innovative artificial intelligence solutions that empower providers and professionals to accurately, reliably and quickly detect cancer and improve outcomes – optimizing every patient’s opportunity to live better, longer lives.
Scientific Presentations
Oral Presentations
A. Nitrosi, P. Giorgi Rossi, L. Verzellesi, N. Cucurachi, R. Vacondio, C. Campari, M. Bertolini, P. Pattacini, M. Iori; Reggio Emilia/IT
Adding artificial intelligence (AI) case malignancy scoring in a breast screening program to reduce screen-reading workload: a retrospective study
- RPS 1202, Artificial intelligence (AI) in breast imaging
- 2024-03-01 08:00 – 09:00
Axel Gräwingholt, MD, Radiologie am Theater, Paderborn, Germany
Retrospective evaluation of interval breast cancer: Can the number of interval carcinomas be reduced utilizing AI diagnostic software?
- RPS 2305, Artificial Intelligence & Machine Learning
- 2024-03-03 09:30 – 11:00
A. Nitrosi, P. Giorgi Rossi, L. Verzellesi, N. Cucurachi, R. Vacondio, C. Campari, M. Bertolini, P. Pattacini, M. Iori; Reggio Emilia/IT
Adding artificial intelligence (AI) case scoring in a breast screening program to overcame delay in most probably true positive cases: a retrospective study
- RPS 2405, AI in breast cancer screening
- 2024-03-03 11:30 – 12:30
Poster Presentations
Chirag R. Parghi, MD, Chief Medical Officer, Solis Mammography
Breast Arterial Calcification (BAC) as a Proxy for Broader Vessel Disease: BAC Scoring Compared to Atherosclerotic Disease on Companion Computed Tomography (CT) Imaging
- EPOS: Abstract #19050
Meet the Experts
Visit our booth X1 AI-35 for a unique opportunity to meet global experts who are blazing the trail in personalized breast care.
Axel Gräwingholt, MD, Radiologie am Theater, Paderborn, Germany
- X1 AI-35
- Thursday, Feb 29 | 14:00-17:00, Friday, Mar 1 | 10:00-12:00
Learning Opportunities
ProFound Breast Health Suite Workshops
Corinne Baleyguier, Gustave Roussy institute Paris-France
Adoption of artificial intelligence in breast imaging for the work-up set-up
GE Booth – Foyer F
Sunday, February 28, 2024 | 2:00 to 3:00pm & 15:30 to 16:30pm
Axel Gräwingholt, MD, Radiologie am Theater, Paderborn, Germany
Impact of AI in clinical routine for the detection of breast cancer on mammograms
GE Booth – Foyer F
Friday, March 1, 2024 | 2:00 to 3:00pm & 15:30 to 16:30pm
Sponsored by
Introducing iCAD’s AI Platform
ProFound Breast Health Suite
Backed by science, clinical evidence, and proven patient outcomes; our suite of solutions – Detection, Density, and Risk — shine a spotlight on cancer, exposing its hiding place. These clinically proven AI-powered solutions provide certainty and peace of mind, improving patient outcomes and saving more lives.
“Profound AI is my best friend radiologist, looking over my shoulder, never tired and always available”.
Dr. Isabelle Biltjes,
RAdiollogits, AZ Klina, Brasschaat, Belgium
Patient-Driven, AI-Powered
Creating a World Where Cancer Can’t Hide.
Flexible integrations to maximize patient care.
Streamlining mammography workflows to create efficiencies and peace of mind.
With thousands of installations worldwide, our solutions offer multi-vendor compatibility that seamlessly integrate into the diagnostic process, in any reading environment.
Implementation and operation made easy.
Multi-Vendor Capability
Fully integrated with:
• 50+ PACS and 94 versions
• 2D and 3D OEM manufacturers
• AI platform providers and workflow systems
Multi-Deployment Options
• Cloud – yours or ours Coming soon
• On-premises hardware – yours or ours
• 3rd party Platform or OEM integration
Reserve time in-person or virtually.
We look forward to meeting with you.
Let us show you our suite of clinically proven AI-powered breast cancer detection, density assessment, and risk evaluation solutions provide certainty and peace of mind, improving patient outcomes and saving lives.
Disclaimer:
• ProFound AI (new 4th generation) is pending CE Mark, Health Canada, and FDA Clearance.
• ProFound AI Risk is CE Marked, Health Canada Licensed, and available for investigational use only in the U.S.